preclinical-evaluation-of-new-antifibrotics-in-nash-induced-fibrosis-models

Whitepaper - Preclinical Evaluation of new Antifibrotics in NASH-Induced Fibrosis Models

Replicating human NASH in animal models is not possible due to the variable interplay between environmental factors and genetic determinants observed in humans. Nevertheless, preclinical animal models are essential to understanding NASH pathophysiology and testing new antifibrotics.

At Aragen Scientists have created CDAHFD induced NASH mouse model that shows inflammatory infiltrate and pattern of liver fibrosis observed in human NASH. These models are good for pharmacologic testing of novel antifibrotics and are most useful to investigate critical etiopathogenic factors.

Download this whitepaper authored by Dr Nagendra Ningaraj to read in-house as well as client-sponsored study data developed over several years using rodent models.

Please fill the form to download the whitepaper

✽

By submitting this form you agree to our Privacy Policy concerning the way Aragen may use your personal information.

.